As of June 20, 2025, Oasmia Pharmaceutical AB (OASM.ST) reports a Current Ratio of 3.46.
Current Ratio assesses a company's ability to pay short-term debts by comparing liquid assets to liabilities, with higher ratios signaling better financial health.
Historical Trend of Oasmia Pharmaceutical AB's Current Ratio
Over recent years, Oasmia Pharmaceutical AB's Current Ratio has shown significant volatility. The table below summarizes the historical values:
| Date | Current Ratio |
|---|---|
| 2021-12-31 | 3.46 |
| 2020-12-31 | 2.35 |
| 2020-04-30 | 3.00 |
| 2019-04-30 | 0.77 |
| 2018-04-30 | 0.36 |
This slight upward trend highlights how Oasmia Pharmaceutical AB manages its short-term assets and liabilities over time.
Comparing Oasmia Pharmaceutical AB's Current Ratio to Peers
To better understand Oasmia Pharmaceutical AB's position, it's useful to compare its Current Ratio against industry peers. Below are selected comparisons:
| Company | Current Ratio |
|---|---|
| Oasmia Pharmaceutical AB (OASM.ST) | 3.46 |
| Vicore Pharma Holding AB (VICO.ST) | 16.50 |
| Kancera AB (KAN.ST) | 10.61 |
| Destiny Pharma PLC (DEST.L) | 9.89 |
| Biogaia AB (BIOG B.ST) | 7.81 |
| OptiBiotix Health PLC (OPTI.L) | 7.67 |
Compared to its competitors, Oasmia Pharmaceutical AB's Current Ratio is about average compared to peers, reflecting balanced short-term asset management.